search
Back to results

Melatonin Plus Aminoacids for Sarcopenic Elderly (MelAASarc)

Primary Purpose

Sarcopenia

Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Melatonin 1mg
Essential Aminoacids (eAA)
Essential Aminoacids + melatonin
Placebo
Sponsored by
Azienda di Servizi alla Persona di Pavia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sarcopenia

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Aged > or equal 65 years
  • Sarcopenic patients, following the Rosetta Study criteria: Skeletal Muscle Index [SMI] was <7.23 kg/m2 in men and <5.45 kg/m2 in women) and loss of strength, evaluated by dynamometer and defined as <30 kg for men and <20 kg for women, using the average value of the two handgrip measurements of the dominant hand.

Exclusion Criteria:

  • acute illnesses
  • severe liver dysfunction
  • severe heart dysfunction
  • severe kidney dysfunction
  • severe dementia
  • uncontrolled diabetes
  • dysthyroidism
  • any endocrinopathies
  • neoplasia
  • patients treated with steroids
  • patients entirely unable to walk

Sites / Locations

  • Geriatric physical medicine and rehabilitation division at the Istituto Santa Margherita - Azienda di Servizi alla Persona di Pavia

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Placebo Comparator

Experimental

Experimental

Experimental

Arm Label

Placebo (P)

Melatonin (M)

Essential Aminoacids (eAA)

Essential Aminoacids + Melatonin (eAAM)

Arm Description

Placebo.

1 mg/day of melatonin.

4 g/day of essential aminoacids

4 g/day of essential aminoacids and 1 mg/day of melatonin

Outcomes

Primary Outcome Measures

Change in Total Fat Mass and Total Free Fat Mass (DXA)
Body composition by dual-energy X-ray absorptiometry (DXA). Body composition was measured by DXA, using a Lunar Prodigy DXA (GE Medical Systems, Waukesha, WI). Free Fat mass and Fat mass of specific body regions were measured in kilograms.
Change in Handgrip Strenght
Handgrip strength assessed using a Jamar dynamometer adhering to the standardized protocol recommended by the American Society of Hand Therapists. A weak handgrip was defined as <30 kg for men and <20 kg for women, based on the average value of the two handgrip measurements of the dominant hand

Secondary Outcome Measures

Height
Height measured in meters
Change in Body Weight
Body Weight measured in kilograms
Change in serum proteins
Serum proteins and albumin were measured by automatic biochemical analyzer. They were reported as g/dl
Change in blood lipids (total cholesterol and triglycerides)
Blood lipids (total cholesterol and triglycerides)were measured by automatic biochemical analyzer. They were reported as mg/dl
Change in High-sensitivity C-reactive protein (CRP)
High-sensitivity C-reactive protein (CRP) was expressed in mg/dl.
Change in erythrocyte sedimentation rate (ESR)
Erythrocyte sedimentation rate (ESR) was expressed in mm/hr.
Change in glycaemia
glycemia was expressed in mg/dl
Change in Mini Nutritional Assessment (MNA)
A mini nutritional assessment (MNA) was performed for all participants. The MNA uses 18 questions regarding simple measurements and a brief questionnaire involving an anthropometric assessment (weight, height and weight loss), a general assessment (lifestyle, medication and mobility), and a dietary assessment (number of meals, food and fluid intake, self-assessment of eating autonomy and self-perception of health and nutrition). Every answer give up to a maximum of 3 points. The sum of all points gives the total MNA. A maximum of 30 points can be achieved. A score of ≥ 24 points describes a well-nourished status. A score of 17 to 23.5 points indicates a risk of malnutrition, while less than 17 points indicates malnutrition.
Change in dietary intake
A trained dietitian used a calibrated dietetic spring scale to weigh all foods served and returned for 3 consecutive days at the beginning and end of the study

Full Information

First Posted
December 14, 2018
Last Updated
December 21, 2018
Sponsor
Azienda di Servizi alla Persona di Pavia
search

1. Study Identification

Unique Protocol Identification Number
NCT03784495
Brief Title
Melatonin Plus Aminoacids for Sarcopenic Elderly
Acronym
MelAASarc
Official Title
Is a Combination of Melatonin and Aminoacids Useful to Sarcopenic Elderly Patients? A Randomized Trial
Study Type
Interventional

2. Study Status

Record Verification Date
December 2018
Overall Recruitment Status
Completed
Study Start Date
January 1, 2014 (Actual)
Primary Completion Date
December 31, 2014 (Actual)
Study Completion Date
June 1, 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Azienda di Servizi alla Persona di Pavia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
To evaluate the effectiveness of melatonin and essential aminoacid supplementation on body composition, protein metabolism, strength and inflammation. The investigators performed a Randomized controlled parallel groups preliminary trial in 159 elderly sarcopenic people (42/117 men/women) assigned to 4 groups: isocaloric placebo (P, n=44), melatonin (M, 1 mg/daily, n=42,), essential aminoacids (eAA 4 g/daily, n=40) or eAA plus melatonin (eAAM, 4 g eAA and 1 mg melatonin/daily, n= 30). The period of intervention was 4 weeks. Data from body composition (DXA), strength (handgrip test) and biochemical parameters for the assessment of protein metabolism (albumin) and inflammation (PRC) were collected at baseline and after the 4-week intervention

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sarcopenia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
159 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo (P)
Arm Type
Placebo Comparator
Arm Description
Placebo.
Arm Title
Melatonin (M)
Arm Type
Experimental
Arm Description
1 mg/day of melatonin.
Arm Title
Essential Aminoacids (eAA)
Arm Type
Experimental
Arm Description
4 g/day of essential aminoacids
Arm Title
Essential Aminoacids + Melatonin (eAAM)
Arm Type
Experimental
Arm Description
4 g/day of essential aminoacids and 1 mg/day of melatonin
Intervention Type
Drug
Intervention Name(s)
Melatonin 1mg
Intervention Description
1 mg/day 30 minutes before sleep
Intervention Type
Dietary Supplement
Intervention Name(s)
Essential Aminoacids (eAA)
Intervention Description
4g/day of Essential Aminoacids during breakfast. Packets of powdered amino acid supplements (42.0% leucine, 14.0% lysine, 10.5% valine, 10.5% isoleucine, 10.5% threonine, 7.0% phenylalanine, and 5.5% other) were provided for the participants to be taken with water or milk, and they were instructed to take the 4-gram supplement once a day every day for 4 weeks.
Intervention Type
Combination Product
Intervention Name(s)
Essential Aminoacids + melatonin
Intervention Description
4g/day of Essential Aminoacids during breakfast + 1 mg/day of Melatonin 30 minutes before sleep. Packets of powdered amino acid supplements (42.0% leucine, 14.0% lysine, 10.5% valine, 10.5% isoleucine, 10.5% threonine, 7.0% phenylalanine, and 5.5% other) were provided for the participants to be taken with water or milk, and they were instructed to take the 4-gram supplement once a day every day for 4 weeks.
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
an isocaloric amount of maltodextrin with the same flavor and appearance as the intervention product
Primary Outcome Measure Information:
Title
Change in Total Fat Mass and Total Free Fat Mass (DXA)
Description
Body composition by dual-energy X-ray absorptiometry (DXA). Body composition was measured by DXA, using a Lunar Prodigy DXA (GE Medical Systems, Waukesha, WI). Free Fat mass and Fat mass of specific body regions were measured in kilograms.
Time Frame
0, 30 days
Title
Change in Handgrip Strenght
Description
Handgrip strength assessed using a Jamar dynamometer adhering to the standardized protocol recommended by the American Society of Hand Therapists. A weak handgrip was defined as <30 kg for men and <20 kg for women, based on the average value of the two handgrip measurements of the dominant hand
Time Frame
0, 30 days
Secondary Outcome Measure Information:
Title
Height
Description
Height measured in meters
Time Frame
At baseline (0)
Title
Change in Body Weight
Description
Body Weight measured in kilograms
Time Frame
0, 30 days
Title
Change in serum proteins
Description
Serum proteins and albumin were measured by automatic biochemical analyzer. They were reported as g/dl
Time Frame
0, 30 days
Title
Change in blood lipids (total cholesterol and triglycerides)
Description
Blood lipids (total cholesterol and triglycerides)were measured by automatic biochemical analyzer. They were reported as mg/dl
Time Frame
0, 30 days
Title
Change in High-sensitivity C-reactive protein (CRP)
Description
High-sensitivity C-reactive protein (CRP) was expressed in mg/dl.
Time Frame
0, 30 days
Title
Change in erythrocyte sedimentation rate (ESR)
Description
Erythrocyte sedimentation rate (ESR) was expressed in mm/hr.
Time Frame
0, 30 days
Title
Change in glycaemia
Description
glycemia was expressed in mg/dl
Time Frame
0, 30 days
Title
Change in Mini Nutritional Assessment (MNA)
Description
A mini nutritional assessment (MNA) was performed for all participants. The MNA uses 18 questions regarding simple measurements and a brief questionnaire involving an anthropometric assessment (weight, height and weight loss), a general assessment (lifestyle, medication and mobility), and a dietary assessment (number of meals, food and fluid intake, self-assessment of eating autonomy and self-perception of health and nutrition). Every answer give up to a maximum of 3 points. The sum of all points gives the total MNA. A maximum of 30 points can be achieved. A score of ≥ 24 points describes a well-nourished status. A score of 17 to 23.5 points indicates a risk of malnutrition, while less than 17 points indicates malnutrition.
Time Frame
0, 30 days
Title
Change in dietary intake
Description
A trained dietitian used a calibrated dietetic spring scale to weigh all foods served and returned for 3 consecutive days at the beginning and end of the study
Time Frame
Measures taken at day 1,2,3 and at day 28,29,30

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged > or equal 65 years Sarcopenic patients, following the Rosetta Study criteria: Skeletal Muscle Index [SMI] was <7.23 kg/m2 in men and <5.45 kg/m2 in women) and loss of strength, evaluated by dynamometer and defined as <30 kg for men and <20 kg for women, using the average value of the two handgrip measurements of the dominant hand. Exclusion Criteria: acute illnesses severe liver dysfunction severe heart dysfunction severe kidney dysfunction severe dementia uncontrolled diabetes dysthyroidism any endocrinopathies neoplasia patients treated with steroids patients entirely unable to walk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mariangela Rondanelli, Professor
Organizational Affiliation
IRCCS Mondino Foundation, Pavia
Official's Role
Study Director
Facility Information:
Facility Name
Geriatric physical medicine and rehabilitation division at the Istituto Santa Margherita - Azienda di Servizi alla Persona di Pavia
City
Pavia
ZIP/Postal Code
27100
Country
Italy

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
IPD will be not available for other researchers

Learn more about this trial

Melatonin Plus Aminoacids for Sarcopenic Elderly

We'll reach out to this number within 24 hrs